ALXO vs. OPK, SPRY, IMNM, SAGE, TNGX, ELVN, ETNB, ARQT, TYRA, and ZNTL
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include OPKO Health (OPK), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Sage Therapeutics (SAGE), Tango Therapeutics (TNGX), Enliven Therapeutics (ELVN), 89bio (ETNB), Arcutis Biotherapeutics (ARQT), Tyra Biosciences (TYRA), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry.
OPKO Health (NASDAQ:OPK) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
In the previous week, OPKO Health had 1 more articles in the media than ALX Oncology. MarketBeat recorded 14 mentions for OPKO Health and 13 mentions for ALX Oncology. OPKO Health's average media sentiment score of 0.69 beat ALX Oncology's score of -0.12 indicating that ALX Oncology is being referred to more favorably in the news media.
OPKO Health currently has a consensus target price of $3.17, indicating a potential upside of 147.40%. ALX Oncology has a consensus target price of $18.83, indicating a potential upside of 16.18%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe OPKO Health is more favorable than ALX Oncology.
OPKO Health has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
ALX Oncology has a net margin of 0.00% compared to ALX Oncology's net margin of -21.76%. ALX Oncology's return on equity of -12.69% beat OPKO Health's return on equity.
64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 47.3% of OPKO Health shares are owned by company insiders. Comparatively, 50.3% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ALX Oncology has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.
OPKO Health received 458 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 65.87% of users gave OPKO Health an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
Summary
OPKO Health beats ALX Oncology on 10 of the 17 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
